Related Experiment Video

Updated: Dec 26, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications

Noa Biran1, David H Vesole1, Michele L Donato1

  • 1Noa Biran, MD; David H. Vesole, MD, PhD; Michele L. Donato, MD; Andrew Ip, MD; Gurbakhash Kaur, MD; Stuart Goldberg, MD; and David S. Siegel, MD, PhD; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 12, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K